scholarly journals Decreasing Extra Tube Collections in a Healthcare System

2020 ◽  
Vol 154 (Supplement_1) ◽  
pp. S150-S150
Author(s):  
K M Evans
Keyword(s):  
Cost Effectiveness ◽  
Healthcare System ◽  
Best Practice ◽  
Blood Conservation ◽  
Upper Management ◽  
Internal Database ◽  
Practice Committee

Abstract Introduction/Objective To determine a mechanism for obtaining and utilizing data on extra specimens collected that were not used, monitoring collections and decreasing the need to collect these specimens in order to save the patient’s blood from being wasted, as well as the resources used to collect and house the extra specimens. Methods Internal database, Sunquest, and Tableau Results Starting in early 2017, statistics were pulled and analyzed by our Phlebotomy Best Practice committee in order to obatin a solid basis to review all extra specimens being collected (excluding blue, lavender, and lithium herparin tubes) by phlebotomy in order to save teh patient’s blood from being disposed of without being used for testing, continue to look for ways to maintain blood conservation and collections, cost effectiveness due to not having to use the supplies, as well as store the specimens that were not being used for testing. Conclusion As of January 2020, there has been a 30% decrease in collections (yearly - over 3 years), and a maximum 45% decrease in cost (thus far) of supplies and waste. It has been a larage patient and upper management satisfier; patient’s don’t question the number of tubes being taken, and the decrease in spending makes the VP happy!

scholarly journals Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy

BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e036599
Author(s):  
Sedona Sweeney ◽  
Gabriela Gomez ◽  
Nichola Kitson ◽  
Animesh Sinha ◽  
Natalia Yatskevich ◽  
...  
Keyword(s):  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Best Practice ◽  
Current Treatment ◽  
Outcome Data ◽  
London School ◽  
Main Trial ◽  
Ethical Approval ◽  
Mdr Tb ◽  
The Impact

IntroductionCurrent treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are much greater than those for treating drug-susceptible TB, both for health service and patient-incurred costs. Urgent action is needed to identify short, effective, tolerable and cheaper treatments for people with both quinolone-susceptible and quinolone-resistant MDR-TB. We present the protocol for an economic evaluation (PRACTECAL-EE substudy) alongside an ongoing clinical trial (TB-PRACTECAL) aiming to assess the costs to patients and providers of new regimens, as well as their cost-effectiveness and impact on participant poverty levels. This substudy is based on data from the three countries participating in the main trial.Methods and analysisPrimary cost data will be collected from the provider and patient perspectives, following economic best practice. We will estimate the probability that new MDR-TB regimens containing bedaquiline, pretomanid and linezolid are cost-effective from a societal perspective as compared with the standard of care for MDR-TB patients in Uzbekistan, South Africa and Belarus. Analysis uses a Markov model populated with primary cost and outcome data collected at each study site. We will also estimate the impact of new regimens on prevalence of catastrophic patient costs due to TB.Ethics and disseminationEthical approval has been obtained from the London School of Hygiene & Tropical Medicine and Médecins Sans Frontières. Local ethical approval will be sought in each study site. The results of the economic evaluation will be shared with the country health authorities and published in a peer-reviewed journal.Trial registration numberClinicalTrials.gov Registry (NCT04207112); Pre-results.

PP329 An Australian Cost-Effectiveness Analysis Of The EluviaTM Drug-Eluting Stent For Treatment Of Symptomatic Lower-Limb Peripheral Artery Disease

2020 ◽  
Vol 36 (S1) ◽  
pp. 28-29
Author(s):  
William A. Gray ◽  
Thathya V. Ariyaratne ◽  
Robert I. Griffiths ◽  
Peter W.M. Elroy ◽  
Stacey L. Amorosi ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Healthcare System ◽  
Lower Limb ◽  
Sensitivity Analyses ◽  
Public Healthcare ◽  
System Perspective ◽  
Healthcare System Perspective ◽  
Drug Eluting ◽  
Zilver Ptx ◽  
Cost Parameters

IntroductionDespite advances in endovascular interventions, including the introduction of drug-eluting stents (DES), high target lesion revascularization (TLR) rates still burden the treatment of symptomatic lower-limb peripheral arterial disease (PAD). EluviaTM, a novel, sustained-release, paclitaxel-eluting DES, was shown to further reduce TLRs when compared with the paclitaxel-coated Zilver® PTX® stent, in the IMPERIAL randomized controlled trial. This evaluation estimated the cost-effectiveness of Eluvia when compared with Zilver PTX in Australia, based on 12-month clinical outcomes from the IMPERIAL trial.MethodsA state-transition, decision-analytic model with a 12-month time horizon was developed from an Australian public healthcare system perspective. Cost parameters were obtained from the Australian National Hospital Cost Data Collection Cost Report (2016–17). All costs were captured in Australian dollars (AUD), where AUD 1 = USD 0.69 (June 2020). Complete sets of clinical parameters (primary patency loss, TLR, amputation, and death) and cost parameters from their respective distributions were bootstrapped in samples of 1,000 patients, for each intervention arm of the model. One-way and probabilistic sensitivity analyses were performed.ResultsAt 12 months, modeled TLR rates were 4.5 percent for Eluvia and 8.9 percent for Zilver PTX, and mean total direct costs were AUD 6,537 [USD 4,511] and AUD 6,908 [USD 4,767], respectively (Eluvia average per patient savings; overall cohort=AUD 371 [USD 256]; diabetic cohort=AUD 625 [USD 431]). In probabilistic sensitivity analyses, Eluvia was cost-effective relative to Zilver PTX in 92.0 percent of all simulations at a threshold of $10,000 per TLR avoided. Eluvia was more effective and less costly (dominant) than Zilver PTX in 76.0 percent of simulations.ConclusionsIn the first year after the intervention, Eluvia was more effective and less costly than Zilver PTX, making Eluvia the dominant treatment strategy for treatment of symptomatic lower-limb PAD, from an Australian public healthcare system perspective. These findings should be considered when formulating policy and practice guidelines in the context of priority setting and making evidence-based resource allocation decisions for treatment of PAD in Australia.

Abstract NS20: Improving Stroke Evidenced-Based Best Practices Across a Multi-State Healthcare System

Stroke ◽  
2014 ◽  
Vol 45 (suppl_1) ◽  
Author(s):  
Deborah Camp ◽  
Ann Mroz ◽  
Tina Cronin ◽  
Maria Fernandez
Keyword(s):  
Patient Education ◽  
Best Practices ◽  
Healthcare System ◽  
Best Practice ◽  
Group Development ◽  
Quality Metrics ◽  
Collaborative Group ◽  
Conference Calls ◽  
Evidenced Based ◽  
Get With The Guidelines

Background and Purpose: As a National effort to provide a framework to improve stroke best practices, a multi- center healthcare system with 48 hospitals across ten states established a stroke collaborative working group. The purpose was to develop a forum to standardize and improve stroke evidenced-based best practices with sister facilities. Methods: A questionnaire was developed and distributed to the stroke collaborative group. A telephone conference was held to review survey results and organizational trends from the 2010 Get With The Guidelines (GWTG) stroke quality metrics. Three quality metrics, dysphagia screening, patient education and door to needle (DTN) were initially identified along with establishing three subcommittees to focus upon improving best practices for each of these measures. Educational webinars, best practice successes and barriers were shared on monthly conference calls as well as a development of an email stroke distribution list serve to improve communication. Results: The three chosen GWTG stroke quality metric score aggregates from 2010 to 2013 second quarter were: dysphagia screen 78.8% to 85.7%, patient education 86% to 94.6%, DTN 60 minutes or less 31% to 72.8% with a mean DTN time of 91 minutes to 68.8 minutes. Conclusion: Formation of a stroke collaborative group for this organization had a positive effect on improving stroke best practices. Areas of focus identified were standardized best practice processes which included creation of system-wide electronic stroke order sets, development of staff and patient educational materials, implementation of templates and development of a DTN challenge. As the Stroke Collaborative expanded three additional working subcommittees were established, Patient Satisfaction, Emergency Medical Service collaboration and Stroke Support Group Development. In conclusion facilitation of communication and collaboration utilizing individual talents and resources is an effective way to improve stroke evidenced-based best practice across a multi-state healthcare system.

scholarly journals The Cost-Effectiveness of the Integration of Nalmefene within the UK Healthcare System Treatment Pathway for Alcohol Dependence

2016 ◽  
Vol 51 (3) ◽  
pp. 283-290 ◽  
Author(s):  
Philippe Laramée ◽  
Melissa Bell ◽  
Adam Irving ◽  
Thor-Henrik Brodtkorb
Keyword(s):  
Cost Effectiveness ◽  
Alcohol Dependence ◽  
Healthcare System ◽  
Treatment Pathway ◽  
The Uk ◽  
The Cost
Sign in / Sign up

Export Citation Format

Share Document